Loading clinical trials...
Loading clinical trials...
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Conditions
Interventions
Pamrevlumab
Locations
10
United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
University of California San Francisco - Benioff Children's Hospital
San Francisco, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Rare Disease Research
Atlanta, Georgia, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Washington University in St. Louis School of Medicine
St Louis, Missouri, United States
Start Date
January 4, 2016
Primary Completion Date
May 7, 2020
Completion Date
August 9, 2023
Last Updated
August 27, 2024
NCT06817382
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
Lead Sponsor
Kyntra Bio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions